<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667978</url>
  </required_header>
  <id_info>
    <org_study_id>HS-12-00005</org_study_id>
    <nct_id>NCT01667978</nct_id>
  </id_info>
  <brief_title>The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception</brief_title>
  <acronym>NET</acronym>
  <official_title>The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if women taking the atazanavir and ritonavir have lower&#xD;
      levels of a birth control medication called norethindrone. Norethindrone (also called the&#xD;
      mini pill) is an FDA (Food and Drug Administration) approved progestin-only birth control&#xD;
      pill used to prevent pregnancy. Norethindrone is the standard medication used in women who&#xD;
      take the progestin only pill to prevent pregnancy. There are other birth control pills which&#xD;
      contain different medications. The investigators want to learn if HIV medications (atazanavir&#xD;
      and ritonavir) make the blood level of this birth control pill higher or lower. If the levels&#xD;
      of norethindrone are too low it may not work to prevent pregnancy. The investigators also&#xD;
      hope to learn about changes in the vaginal fluids and cervical fluids when women are taking&#xD;
      this birth control pill.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND/RATIONALE : It is recognized that there is a dearth of clinically applied,&#xD;
      population based, empiric data to guide contraceptive recommendations in HIV + women on&#xD;
      ARVs.(1) Protease inhibitors (PI) and non nucleoside reverse transcriptase inhibitors (NNRTI&#xD;
      ) induce micro enzyme systems such as CYP 3a4, which in turn alters the bio-availability and&#xD;
      pharmacokinetics of other concurrently administered medications.(2) Empiric trials from small&#xD;
      samples, often of 10-20 HIV negative subjects, have demonstrated that concurrent&#xD;
      administration of combined oral contraceptives (COC) and a PI or a NNRTI have been associated&#xD;
      with decreased plasma ethinyl estradiol (EE) levels. These pharmacokinetic findings have&#xD;
      raised concern that decreased bio-availability of EE may result in decreased contraceptive&#xD;
      efficacy, with possible increased unintended pregnancy. Some of these COC studies have&#xD;
      demonstrated that there is no change in the serum levels of norethindrone (NET) on&#xD;
      ARVs.(3-16) However, there are no published trials focused on oral NET or oral progestin-only&#xD;
      pills (POP) to guide management in HIV+ women.(17)&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      Primary objective of this study is:&#xD;
&#xD;
      To detect a Â±40% difference in AUC of serum NET in HIV+ women taking ATV/RTV as compared to&#xD;
      AUC of NET in HIV+ women taking an ARV regimen that has demonstrated no interaction with NET&#xD;
      in the past.&#xD;
&#xD;
      Primary endpoint: Natural log-transformed NET PK parameter AUC from 0 to 72 hours following&#xD;
      oral administration, with multiple discrete serum data points for each subject on ATV/RTV.&#xD;
      This will be compared to natural log-transformed NET PK AUC from 0 to 72 hours following oral&#xD;
      administration, with multiple discrete serum data points for controls HIV+ women taking an&#xD;
      ARV regimen that has demonstrated no interaction with NET in the past.&#xD;
&#xD;
      The secondary objectives of this study are:&#xD;
&#xD;
      To evaluate the effect of ATV/RTV on other PK exposure endpoints and parameters of NET (with&#xD;
      natural log transformation). The sample and control groups mentioned above will again be&#xD;
      compared. Endpoints include:&#xD;
&#xD;
      minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), time to Cmax&#xD;
      (Tmax), and half-life (T1/2).&#xD;
&#xD;
      SAMPLE SIZE: Recruitment of 16 participants in each arm, with the goal of attaining 32&#xD;
      evaluable HIV-1-seropositive female subjects in total.&#xD;
&#xD;
      POPULATION/STUDY ARMS: HIV-1-infected female subjects 18-44 years of age&#xD;
&#xD;
      METHODOLOGY/INTERVENTIONS/FOLLOW-UP: A two-arm, open-label, prospective, steady state trial&#xD;
      to characterize the pharmacokinetics (PK) of oral norethindrone (NET) as a progestin only&#xD;
      contraceptive pill (POP) in HIV+ women receiving atazanavir and ritonavir therapy (ATV/RTV).&#xD;
      The investigators will identify a control group of HIV+ women who are taking ARV regimens&#xD;
      that have not significantly altered oral NET levels in prior trials. Subjects will be&#xD;
      enrolled in the trial for approximately 4 weeks A 28 day continuous packet of NET 0.35 mg&#xD;
      will be provided to all enrolled volunteers for 21 days of continuous administration. Women&#xD;
      who participate in this study will demonstrate a means of continuing their ARV regimens for&#xD;
      the duration of the study, ARV therapy will not be provided by this study. On day 22 subjects&#xD;
      will be admitted for serial pharmacokinetic (PK) specimens collection following the final&#xD;
      study dose of NET.&#xD;
&#xD;
      Subjects will be enrolled into one of the 2 arms based on their current ARV regimen.&#xD;
&#xD;
      Study group: Women on stable ARV/RTV (300/100mg daily) with additional ARV regimens that have&#xD;
      not significantly altered oral NET levels in prior trials. (n=12).&#xD;
&#xD;
      Control group: Stable on current ARV, no protease inhibitors (PI), ARV regimens that have not&#xD;
      significantly altered oral NET levels in previous research.&#xD;
&#xD;
      OUTCOMES: Intensive PK sampling for NET will be performed in those in intervention and&#xD;
      control arms after 21 days of NET administration. To determine side effect profile of NET by&#xD;
      self-administered daily questionnaire during the 3-4 week study enrollment period&#xD;
&#xD;
      STATISTICS: Area under the concentration-time curve (AUC), peak plasma concentration, and the&#xD;
      lowest plasma concentration for NET in HIV+ women receiving this PI therapy will be&#xD;
      determined and compared to similar values in HIV positive control subjects who are not taking&#xD;
      PI therapy. Statistical consultation will be obtained from the USC Keck School of Medicine&#xD;
      Department of Bio statistics and Laboratory of Applied Pharmacokinetics&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC Norethindrone</measure>
    <time_frame>following 21 days of continuous ingestion</time_frame>
    <description>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 21</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Pregnancy</condition>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>PI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study group with PI: atazanavir ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>o PI therapy, control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone acetate</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PI</arm_group_label>
    <other_name>Both control and experimental group with take norethindrone. However the experimental group will be taking a protease inhibitor: atazanavir and ritonavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Ages: 18-44 years Gender: female Accepts: healthy volunteers and HIV-1 infected women&#xD;
        Acceptable medications include: no other medications, NRTI combinations, entry inhibitors,&#xD;
        integrase inhibitors, and CCR5 agonists. NRTI combinations may include but are not limited&#xD;
        to: zidovudine (ZDV), lamivudine (3TC), emtricitabine (FTC), didanosine (ddl), stavudine&#xD;
        (d4T), abacavir (ABC), and tenofovir disoproxil fumarate (TDF). NNRTI: etravirine, and&#xD;
        rilpivirine.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        History of bilateral oophorectomy, ovarian dysfunction or no regular periods. CD4+ cell&#xD;
        count &lt;200 cells/mm3 No current or uncontrolled thyroid, liver, or renal disease BMI &lt;40&#xD;
        kg/m^2 Current pregnancy, breastfeeding or pregnancy within 30 days of enrollment.&#xD;
        Depomedroxyprogesterone acetate injection (DMPA) within 180 days prior to study entry.&#xD;
&#xD;
        Other hormonal therapies (e.g. oral contraceptive agents, Provera, vaginal ring,&#xD;
        contraceptive patch, monthly contraceptive injection, hormone replacement therapy, anabolic&#xD;
        therapies, including nandrolone decanoate or megestrol acetate) within the 21 days prior to&#xD;
        study entry.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica M Atrio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County Hospital University of Southern California (LAC USC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles County University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 15, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <results_first_submitted>May 27, 2015</results_first_submitted>
  <results_first_submitted_qc>August 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2015</results_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Jessica Maria Atrio</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>mini pill</keyword>
  <keyword>norethindrone</keyword>
  <keyword>atazanavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>norvir</keyword>
  <keyword>reyataz</keyword>
  <keyword>pregnancy prevent</keyword>
  <keyword>birth control</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>antiviral</keyword>
  <keyword>antiretroviral</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Protease Inhibitor</title>
          <description>Study group with PI: atazanavir ritonavir&#xD;
Norethindrone acetate&#xD;
16 HIV positive on PI (atazanavir ritonavir 10, darunovir, lopinavir)</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>no PI therapy, control group&#xD;
Norethindrone acetate&#xD;
17 controls (4 no ARV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Protease Inhibitor</title>
          <description>Study group with PI: atazanavir ritonavir&#xD;
Norethindrone acetate</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>o PI therapy, control group&#xD;
Norethindrone acetate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" lower_limit="35.9" upper_limit="42.3"/>
                    <measurement group_id="B2" value="38" lower_limit="33.4" upper_limit="41.3"/>
                    <measurement group_id="B3" value="39" lower_limit="34" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC Norethindrone</title>
        <description>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 21</description>
        <time_frame>following 21 days of continuous ingestion</time_frame>
        <population>2 withdrew because unable to present for study visit and another changed her medication</population>
        <group_list>
          <group group_id="O1">
            <title>Protease Inhibitor</title>
            <description>Study group with PI: atazanavir ritonavir&#xD;
Norethindrone acetate</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>o PI therapy, control group&#xD;
Norethindrone acetate</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Norethindrone</title>
          <description>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 21</description>
          <population>2 withdrew because unable to present for study visit and another changed her medication</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.81" lower_limit="19.24" upper_limit="81.71"/>
                    <measurement group_id="O2" value="25.21" lower_limit="15.89" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Protease Inhibitor</title>
          <description>Study group with PI: atazanavir ritonavir&#xD;
Norethindrone acetate</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>o PI therapy, control group&#xD;
Norethindrone acetate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica Atrio</name_or_title>
      <organization>Montefiore</organization>
      <phone>718 405 82 60</phone>
      <email>jatrio@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

